Serum levels of interleukin 6 in patients with lung cancer.
Serum levels of interleukin 6 in patients with lung cancer.
复制标题
肺癌患者的白细胞介素6的血清水平。
DOI：
10.1038/bjc.1995.212
复制
发表时间：
1995-05
影响因子：
8.8
通讯作者：
Ogura, T
中科院分区：
文献类型：
--
作者：
Yanagawa, H;Sone, S;Takahashi, Y;Haku, T;Yano, S;Shinohara, T;Ogura, T
本文测定了75例肺癌和20例肺良性疾病患者血清白细胞介素6（IL-6）水平。IL-6在29例肺癌患者（39%）中可检测到，但在任何良性肺部疾病患者中均未检测到。血清IL-6阳性的肺癌患者血清C-反应蛋白、血浆纤维蛋白原水平显著高于血清IL-6阴性的肺癌患者和肺良性疾病患者，血清白蛋白水平显著低于血清IL-6阴性的肺癌患者。另一方面，在这三组中未观察到血小板计数的显著差异。此外，血清IL-6水平在有或无临床证实的远处转移的肺癌患者中无显著差异。这些结果表明，IL-6可能是各种反应的介质，包括肺癌患者的炎症反应。
Serum interleukin 6 (IL-6) levels were measured in 75 patients with lung cancer and in 20 patients with benign lung diseases. IL-6 was detectable in 29 patients with lung cancer (39%), but was not detectable in any of the patients with benign lung diseases. Serum C-reactive protein levels and plasma fibrinogen levels were significantly higher and serum albumin concentration was significantly lower in lung cancer patients with detectable serum IL-6 levels than in those without detectable serum IL-6 levels and in patients with benign lung diseases. On the other hand, no significant difference was observed in blood platelet counts in these three groups. Moreover, serum IL-6 levels were not significantly different in lung cancer patients with or without clinically demonstrated distant metastasis. These results suggest that IL-6 may be a mediator of various reactions including an inflammatory response in lung cancer patients.